1539276-43-1

Basic information

• Product Name: N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1-methyl-1-pyridin-4-ylethylamino)propyl]-5-piperidin-1-yl-N',N'-dipropylisophthalamide
• CAS NO: 1539276-43-1
• Molecular Weight: 613.844
• Mol File: 1539276-43-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1-methyl-1-pyridin-4-ylethylamino)propyl]-5-piperidin-1-yl-N',N'-dipropylisophthalamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1-methyl-1-pyridin-4-ylethylamino)propyl]-5-piperidin-1-yl-N',N'-dipropylisophthalamide(1539276-43-1)
• EPA Substance Registry System: N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1-methyl-1-pyridin-4-ylethylamino)propyl]-5-piperidin-1-yl-N',N'-dipropylisophthalamide(1539276-43-1)

Safety Data

• Hazardous Substances Data: 1539276-43-1(Hazardous Substances Data)

Upstream product

• 98760-08-8 (1-oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 1539276-77-1 3-(methoxycarbonyl)-5-(piperidin-1-yl)benzoic acid 
• 1108724-51-1 5-piperidin-1-ylisophthalic acid dimethyl ester 
• 110-89-4 piperidine 
• 51760-21-5 dimethyl 5-bromoisophthalate 
• 111-24-0 1,5-dibromo-pentane 
• 149451-80-9 (2S,3S)-3-(t-butoxycarbonylamino)-4-phenylbutane-1,2-diol 
• 103127-52-2 ((S)-1-benzylallyl)carbamic acid tert-butyl ester 
• 566155-76-8 1-methyl-1-pyridin-4-ylethylamine 
• 1539276-88-4 5-piperidin-1-yl-N,N-dipropylisophthalamic acid 
• 1539276-84-0 5-piperidin-1-yl-N,N-dipropylisophthalamic acid methyl ester 

Relevant articles and documents

Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit

Antimalarial hit 1SR (TCMDC-134674) identified in a GlaxoSmithKline cell based screening campaign was evaluated for inhibitory activity against the digestive vacuole plasmepsins (Plm I, II, and IV). It was found to be a potent Plm IV inhibitor with no selectivity over Cathepsin D. A cocrystal structure of 1SR bound to Plm II was solved, providing structural insight for the design of more potent and selective analogues. Structure-guided optimization led to the identification of structurally simplified analogues 17 and 18 as low nanomolar inhibitors of both, plasmepsin Plm IV activity and P. falciparum growth in erythrocytes.